REAL WORLD DATA OF RESPONSE TO DARATUMUMAB PLUS BORTEZOMIB, THALIDOMIDE AND DEXAMETHASONE (VTD) INDUCTION AND USE OF VTD AS BRIDGING CHEMOTHERAPY PRIOR TO AUTOLOGOUS STEM CELL TRANSPLANT (ASCT)

EHA Library, Sneha Fernandes, 421532

REAL-WORLD EXPERIENCE OF QUADRUPLET INDUCTION TREATMENT, DARA-VTD FOR UNTREATED TRANSPLANT ELIGIBLE MYELOMA PATIENTS IN A UK NHS CANCER CENTRE

EHA Library, Salam Youssef, 421533

THE POSSIBILITIES OF USING HIGH-THROUGHPUT SEQUENCING IN PATIENTS WITH MULTIPLE MYELOMA

EHA Library, Daria Chebykina, 421534

COST AND HEALTHCARE UTILIZATION IN PATIENTS DIAGNOSED WITH MONOCLONAL GAMMOPATHY DURING THE EVALUATION OF ANEMIA

EHA Library, Mackenzie Maberry, 421535

SAFETY AND EFFICACY OF AUTOLOGOUS STEM CELL TRANSPLANTATION IN ELDERLY MULTIPLE MYELOMA PATIENTS

EHA Library, arda bayar, 421536

6 CYCLES OF ISATUXIMAB, LENALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE (I-VRD) VS. 3 CYCLES OF I-VRD PLUS HIGH-DOSE MELPHALAN IN IN NEWLY DIAGNOSED LOW-RISK MULTIPLE MYELOMA. THE ELIAS-TRIAL.

EHA Library, Theo Leitner, 421537

C-MYC IS A PREDICTIVE FACTOR OF OUTCOMES IN TRANSPLANT ELIGIBLE ELDERLY MULTIPLE MYELOMA PATIENTS

EHA Library, Fatma Keklik Karadag, 421538

THE CLINICAL CHARACTERISTICS AND PROGNOSTIC MODELS OF PATIENTS WITH HIGH-RISK MULTIPLE MYELOMA WITH A TOTAL SURVIVAL PERIOD OF MORE THAN 3 YEARS.

EHA Library, Juan Li, 421539

MANAGEMENT OF MULTIPLE MYELOMA WITH RENAL FAILURE IN ALGERIA

EHA Library, S.M.Amine BENLAZAR, 421540

DOUBLE VERSUS SINGLE AUTOLOGOUS STEM CELL TRANSPLANT IN ELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: A REAL-WORLD MULTICENTRE REPORT

EHA Library, Danilo De Novellis, 421541

PREDICTORS OF RENAL RESPONSE AND SURVIVAL OUTCOMES IN CAST NEPHROPATHY

EHA Library, Wai Nga Grace Lau, 421543

EVALUATION OF ELRANATAMAB VS EPD, PVD, OR KD IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND PRIOR ANTI-CD38–DIRECTED THERAPY: MAGNETISMM-32

EHA Library, Satoshi Ito, 421544

AL AMYLOIDOSIS : BRIDGING GAPS IN KNOWLEDGE FOR IMPROVED PATIENT OUTCOMES : A RETROSPECTIVE REVIEW

EHA Library, amal chalbaoui, 421545

PATIENTS WITH IDIOPATHIC MULTICENTRIC CASTLEMAN DISEASE WHO RESPOND TO SILTUXIMAB DEMONSTRATE SIGNIFICANT MEAN REDUCTION IN C-REACTIVE PROTEIN LEVELS COMPARED WITH SILTUXIMAB NON-RESPONDERS

EHA Library, JEANFRANCOIS ROSSI, 421546

DARATUMUMAB-BASED THERAPY IN PATIENTS WITH MULTIPLE MYELOMA AT FIRST RELAPSE/PROGRESSION: A MULTICENTER REAL-LIFE STUDY

EHA Library, Fengyan Jin, 421547

COMPREHENSIVE GERIATRIC ASSESSMENT AND CLINICAL OUTCOMES OF MULTIPLE MYELOMA PATIENTS IN A LATIN AMERICAN UNIVERSITY HOSPITAL

EHA Library, Claudia Lucía Sossa-Melo, 421548

A RETROSPECTIVE MULTICENTRE REAL-LIFE EXPERIENCE OF SAFETY OF SUBCUTANEOUS DARATUMUMAB IN PLASMA CELL DISORDERS

EHA Library, Danilo De Novellis, 421549

HETEROGENEITY AMONG FRAIL MYELOMA PATIENTS, FROM ‘FRAIL BASED ON AGE ALONE’ TO ‘ULTRA-FRAIL’, IS ASSOCIATED WITH CLINICAL OUTCOME

EHA Library, Kaz Groen, 421550

DEMOGRAPHIC AND BASELINE CHARACTERISTICS OF PATIENTS IN CARDIAC AMYLOID REACHING FOR EXTENDED SURVIVAL (CARES) PHASE 3 TRIALS ASSESSING SAFETY AND EFFICACY OF ANSELAMIMAB IN LIGHT CHAIN AMYLOIDOSIS

EHA Library, Ashutosh Wechalekar, 421551

CYTOMEGALOVIRUS REACTIVATION IN PATIENTS WITH MULTIPLE MYELOMA TREATED WITH DARATUMUMAB AS FIRST- OR SECOND-LINE THERAPY: A SINGLE INSTITUTION RETROSPECTIVE EXPERIENCE

EHA Library, Danilo De Novellis, 421552

MULTIPLE MYELOMA: 25-YEAR RETROSPECTIVE SINGLE-CENTER STUDY (ST. PETERSBURG, RUSSIA)

EHA Library, Sergey Voloshin, 421553

MONOCLONAL GAMMOPATHY OF UNCERTAIN SIGNIFICANCE IN A MEDIUM SIZED DISTRICT GENERAL HOSPITAL IN THE UNITED KINGDOM

EHA Library, Zarnain Syed, 421554

SINGLE-CENTER EXPERIENCE OF THERAPEUTIC INTENSIFICATION FOLLOWED BY AUTOTRANSPLANTATION OF NON-CRYOPOIETIC STEM CELLS IN MULTIPLE MYELOMA

EHA Library, Salima OUKID, 421555

IMPACT OF DARA-VTD INDUCTION THERAPY ON STEM CELL MOBILIZATION OUTCOMES IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION: A MULTICENTER STUDY.

EHA Library, Roberta Della Pepa, 421556

HIGH RATES OF STRINGENT COMPLETE RESPONSE AND MRD NEGATIVITY AFTER DARATUMUMAB BASED INDUCTION QUADRUPLETS IN TRANSPLANT ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS (TE-NDMM) IN THE REAL-WORLD.

EHA Library, Grigorios Salvaras, 421557

CLINICAL OUTCOMES AND MICROBIOLOGICAL DATA IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS: A RETROSPECTIVE OBSERVATIONAL STUDY OF 92 SUBJECTS

EHA Library, Antonio Solimando, 421558

OUTCOME OF PATIENTS WITH MULTIPLE MYELOMA USING NON-CRYOPRESERVED STEM CELLS TRANSPLANT

EHA Library, Qudrat Ullah, 421559

EVALUATING MYOCARDIAL INVOLVEMENT IN PATIENTS WITH MULTIPLE MYELOMA AT DIFFERENT STAGES ：A CARDIAC MR T1 MAPPING STUDY

EHA Library, Peihong Guo, 421560

THE EFFECT OF CD38 EXPRESSION ON THE BONE MARROW PLASMA CELLS AFTER DARATUMUMAB TREATMENT ON DISEASE OUTCOME IN  MULTIPLE MYELOMA PATIENTS

EHA Library, Muhammed Enes CEYLAN, 421561

ISA-KD TREATMENT: EFFICACY IN MMRR PATIENTS WITH PRE-EXISTING SOFT-TISSUE PLASMACYTOMAS. REAL WORLD EVIDENCE.

EHA Library, María Dunia De Miguel Llorente, 421562

HEAVY/LIGHT CHAIN RESPONSE CRITERIA IN MULTIPLE MYELOMA CORRELATES BETTER WITH PROGNOSIS.

EHA Library, Sunil Lakhwani Lakhwani, 421563

DARATUMUMAB IN MULTIPLE MYELOMA. INITIAL EXPERIENCE IN A SINGLE CENTER IN CHILE.

EHA Library, Marcela Espinoza, 421564

A RETROSPECTIVE STUDY OF TREATMENT AND OUTCOMES OF AL AMYLOIDOSIS IN THE ERA OF MODERN DIAGNOSTICS AND NOVEL THERAPEUTIC AGENTS:  A TERTIARY CARE CENTRE EXPERIENCE FROM NORTHERN INDIA

EHA Library, PRIYANKA MOULE, 421565

DEVELOPMENT AND VALIDATION OF A NOVEL FRAILTY MODEL FOR PATIENTS WITH MULTIPLE MYELOMA

EHA Library, biao tian, 421566

LONG-TERM EFFICACY OF CAR-T THERAPY IN PATIENTS WITH FIRST RELAPSE OR PROGRESSIVE MULTIPLE MYELOMA

EHA Library, Yi Wang, 421567

SELINEXOR AND MELPHALAN CONDITIONING REGIMEN FOR AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA

EHA Library, Jiali Li, 421568

ABSENCE OF PROGRESSION WITHIN THREE YEARS MAY IDENTIFY A SUBGROUP OF LONG-TERM SURVIVORS WITH MULTIPLE MYELOMA

EHA Library, Shuangshuang Jia, 421569

MAGNETISMM-30: A PHASE 1B, OPEN-LABEL STUDY OF ELRANATAMAB IN COMBINATION WITH IBERDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA

EHA Library, Alexander Lesokhin, 421570

AL AMYLOID CARDIOMYOPATHY : UNVEILING THE CARDIAC IMPLICATIONS OF IMMUNOGLOBULIN LIGHT CHAIN AMYLOIDOSIS

EHA Library, amal chalbaoui, 421571

AUTOLOGOUS STEM CELL TRANSPLANTATION FOR MULTIPLE MYELOMA PATIENTS WHOSE MYELOMA DEFINING EVENT WAS SLIM

EHA Library, Iuliana Vaxman, 421572

HEAVY/LIGHT CHAIN ANALYSIS CORRELATES WITH CLINICAL OUTCOMES IN MULTIPLE MYELOMA PATIENTS DURING THE DISEASE HISTORY

EHA Library, Cátia Almeida, 421573

PROGNOSTIC FACTORS INFLUENCING OVERALL SURVIVAL AND EVENT-FREE SURVIVAL IN ELDERLY WITH MULTIPLE MYELOMA

EHA Library, Bizid Inaam, 421574

POTENTIAL OF SERUM B-CELL MATURATION ANTIGEN LEVELS AS A DISEASE MONITORING BIOMARKER IN OLIGOSECRETORY RELAPSED MULTIPLE MYELOMA

EHA Library, Daisuke Ikeda, 421575

ISATUXIMAB-CARFILZOMIB-DEXAMETHASONE IN NOT TRANSPLANT CANDIDATES RRMM. EXPERIENCE IN REAL WORLD EVIDENCE (RWE).

EHA Library, María Dunia De Miguel Llorente, 421576

COMPARATIVE EFFICACY OF TECLISTAMAB VERSUS POMALIDOMIDE PLUS DEXAMETHASONE FOR PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED REFRACTORY MULTIPLE MYELOMA IN ENGLAND

EHA Library, Esther Cheah, 421577

SYSTEMIC MASTOCYTOSIS CLASSIFICATION AND TRYPTASE AND ß-2-MICROGLOBULINE LEVELS HELP IDENTIFY CASES IN WHICH PURIFICATION OF MAST CELLS CAN BE AVOIDED

EHA Library, Miguel Piris Villaespesa, 421578

PLATELET MULTI-OMICS ANALYSIS CONFIRMS HYPERGLYCEMIA AS A RISK FACTOR FOR THROMBOSIS IN JAK2V617F-POSITIVE ESSENTIAL THROMBOCYTHEMIA

EHA Library, Jia Chen, 421579

NATURAL KILLER CELLS IN MUTANT CALRETICULIN-DRIVEN MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Theresa Harm, 421580

SINGLE-CELL RNA SEQUENCING REVEALS THE MOLECULAR AND CELLULAR HETEROGENEITY OF MAST CELLS IN SYSTEMIC MASTOCYTOSIS

EHA Library, Ken-Hong Lim, 421581

IMMUNE PROFILING OF PERIPHERAL BLOOD LEUKOCYTE SUBSETS IN INDOLENT SYSTEMIC MASTOCYTOSIS

EHA Library, Cecilia Karlström, 421582

PROTEOMIC AND FUNCTIONAL ANALYSIS OF PLATELETS FROM ESSENTIAL THROMBOCYTHEMIA PATIENTS

EHA Library, Petros Papadopoulos, 421583

COMPARISON OF THE ENZYMATIC AND CELLULAR PROFILES OF CLINICAL JAK2 INHIBITORS FOR THE TREATMENT OF MYELOFIBROSIS

EHA Library, Ricardo Macarron, 421584

ANALYSIS OF MONOCYTE SUBPOPULATIONS BY FLOW CYTOMETRY IN THE DIFFERENTIAL DIAGNOSIS OF CLONAL VERSUS REACTIVE MONOCYTOSIS IN BLOOD. EXPERIENCE IN A TERTIARY HOSPITAL.

EHA Library, Jose-Maria Raya, 421585

ESSENTIAL THROMBOCYTHEMIA AND POLYCYTHEMIA VERA SHOW DIFFERENT JAK2V617F CLONAL EXPANSION BETWEEN ERYTHROID AND PLATELET LINEAGES

EHA Library, Olivier Mansier, 421587

DECIPHERING THE SPLEEN MICROENVIRONMENT IN MYELOFIBROSIS WITH SPATIAL TRANSCRIPTOMIC

EHA Library, Edoardo Peroni, 421588

THA DYNAMICS OF STROMAL CELLS IN MYELOPROLIFERATIVE NEOPLASMS DURING THE MYELOFIBROSIS.

EHA Library, keiki nagaharu, 421589

PROTEOMIC ANALYSIS OF SERUM OF PATIENTS WITH SYSTEMIC MASTOCYTOSIS

EHA Library, Christos Fokoloros, 421590

THE JAK2 46/1 HAPLOTYPE INFLUENCES PD-L1 EXPRESSION

EHA Library, Gonzalo Carreno Gomez-Tarragona, 421592

PREDICTING CALR MUTATIONS IN MPN USING ROUTINE HEMATOXYLIN AND EOSIN (H&E)-STAINED BONE MARROW BIOPSIES

EHA Library, Saad Bashir, 421593

INTRACELLULAR FUMARATE ACCUMULATION IN MYELOFIBROSYS MESENCHYMAL STROMAL CELLS TRIGGERS CELL SENESCENCE AND FIBROSIS ONSET.

EHA Library, Sebastiano Giallongo, 421594

EVALUATION OF IL-3 RECEPTOR ALPHA CHAIN AS POTENTIAL TARGET IN ADVANCED SYSTEMIC MASTOCYTOSIS

EHA Library, Narges Aghaallaei, 421595

CLONAL EVOLUTION IN SECUNDARY ACUTE MYELOID LEUKEMIA ARISING FROM MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Sandra Martin, 421596

ALLELE POLYMORPHISM OF PLASMA HEMOSTATIC FACTORS GENES IN PRIMARY MYELOFIBROSIS

EHA Library, Natalia Korsakova, 421597

CLINICAL-PATHOLOGICAL CHARACTERIZATION OF MYELOPROLIFERATIVE AND MYELODEPLETIVE PHENOTYPES OF PRIMARY AND SECONDARY MYELOFIBROSIS

EHA Library, Simone Zoletto, 421598

UPREGULATION OF THE S100A8/S100A9 GENES LEADS TO RESISTANCE TO RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS AND MAY BE A DRIVING FACTOR IN BONE MARROW FIBROSIS.

EHA Library, JIAN HUANG, 421599

MUTANT MYELOID GENE CATEGORY MAY PREDICT POOR RESPONSE TO JAK INHIBITORS IN PATIENTS WITH MYELOFIBROSIS

EHA Library, Valentina Boldrini, 421600

USEFULNESS OF THE OPTICAL METHOD FOR PLATELET COUNT IN PATIENTS WITH MYELOFIBROSIS AND INFLUENCE OF THROMBOCYTOPENIA IN THERAPEUTIC MANAGEMENT

EHA Library, Vitor Botafogo, 421601

SORAFENIB TREATMENT IN A CASE OF  CLONAL EOSINOPHILIA WITH A TRIP11:FLT3 FUSION: ACHIEVING MOLECULAR TARGETS TO IMPROVE PROGNOSIS IN RARE DISEASES.

EHA Library, Isabel Montero, 421602

MYELOPROLIFERATIVE NEOPLASMS EMERGENCE AND DEVELOPMENT BASED ON REAL LIFE INCIDENCE AND MATHEMATICAL MODELING

EHA Library, Stephane Giraudier, 421603

HIGH PLATELET COUNT AND HIGH PLATELET-TO-LEUCOCYTES RATIO MAY DIFFERENTIATE POLYCYTHEMIAVERA FROM SECONDARY POLYCYTHEMIA

EHA Library, Manel Kasdallah, 421604

HYPOXIA-INDUCIBLE FACTOR-1 IS PATHOLOGICALLY ACTIVATED BY PIM1 PHOSPHORYLATION IN JAK2V617F MYELOPROLIFERATIVE NEOPLASMS, INITIATING A NON-CANONICAL HYPOXIC RESPONSE THAT DRIVES DISEASE PROGRESSION.

EHA Library, Katherine Bridge, 421605

ERYTHROCYTOSIS AS AN UNUSUAL SYMPTOM IN A COMPOUND HETEROZYGOTE IN THE ABCC6 GENE

EHA Library, Dagmar Pospíŝilová, 421606

THROMBOSES IN POLYCYTHEMIA VERA AND ESSENTIAL THROMBOCYTHEMIA ARE DRIVEN BY HYPOXIA-INDUCIBLE FACTORS (HIFS), INFLAMMATION, AND JAK2 V617F

EHA Library, Josef Prchal, 421607

THROMBIN POTENTIAL OF BLOOD MICROPARTICLES IN PATIENTS WITH PH-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Natalia Silina, 421608

REAL-WORLD DATA DEMONSTRATED THE PROGNOSTIC IMPACT AND RUXOLITINIB DOSE OF MODERATE THROMBOCYTOPENIA IN MYELOFIBROSIS

EHA Library, Kazuya Shimoda, 421609

CONSENSUS ON THE DISEASE MANIFESTATIONS OF HYPEREOSINOPHILIC SYNDROME

EHA Library, Peter Vandenberghe, 421610

JAB-8263, A POTENT BET INHIBITOR, IN MYELOFIBROSIS AND OTHER ADVANCED MYELOID NEOPLASMS: RESULTS FROM A PHASE 1/2A STUDY

EHA Library, Bo Jiang, 421611

IMPACT OF PACRITINIB ON SYMPTOMS IN THROMBOCYTOPENIC MYELOFIBROSIS PATIENTS WHO REQUIRE RED BLOOD CELL TRANSFUSION

EHA Library, Stephen OH, 421612

ESTIMATED COST SAVINGS AND COMPLIANCE WITH TELEMEDICINE IN MYELOPROLIFERATIVE NEOPLASMS: A REAL-WORLD EXPERIENCE

EHA Library, Muhammad Ali Khan, 421613

CLINICAL AND DISEASE CHARACTERISTICS OF PATIENTS WITH MYELOFIBROSIS AND ESSENTIAL THROMBOCYTHEMIA WHO HARBOR A CALRETICULIN (CALR) GENE MUTATION: SUBANALYSIS OF THE MOST STUDY

EHA Library, Naveen Pemmaraju, 421614

EFFICACY AND SAFETY OF RUXOLITINIB IN CHINESE PATIENTS WITH POLYCYTHEMIA VERA RESISTANT/INTOLERANT TO HYDROXYUREA AND/OR INTERFERON-Α: INTERIM ANALYSIS OF A MULTICENTER, PROSPECTIVE, PHASE II STUDY

EHA Library, Zefeng Xu, 421615

ROP-ET: A PROSPECTIVE PHASE III TRIAL INVESTIGATING THE EFFICACY AND SAFETY OF ROPEGINTERFERON ALFA-2B IN ESSENTIAL THROMBOCYTHEMIA PATIENTS WITH LIMITED TREATMENT OPTIONS

EHA Library, Jean-Jacques Kiladjian, 421616

THROMBIN GENERATION IN MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Natalia Silina, 421617

SEVEN-YEAR FOLLOW-UP OF PATIENTS WITH MYELOFIBROSIS TREATED WITH RUXOLITINIB: SINGLE CENTER EXPERIENCE

EHA Library, Stela Dimitrova, 421618

SENSITIVITY EVALUATION OF HETERODUPLEX ANALYSIS METHOD FOR SCREENING JAK2 EXON 12 MUTATIONS

EHA Library, Tatiana Subbotina, 421619

MEGAKARYOCYTE-DERIVED PF4/CXCL4 AND BCR::ABL1-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS: A NEW POTENTIAL PROGNOSTIC FACTOR FOR DISEASE PROGRESSION?

EHA Library, Valentina Bellani, 421620

LONG-TERM SAFETY AND EFFICACY OF ROPEGINTERFERON ALFA-2B FOR PATIENTS WITH POLYCYTHEMIA VERA IN JAPAN

EHA Library, Keita Kirito, 421621

DIAGNOSTIC ACCURACY OF ERYTHROPOIETIN AND JAKPOT IN PREDICTING JAK2-POSITIVE ERYTHROCYTOSIS: A RETROSPECTIVE COHORT STUDY

EHA Library, Sabina Rajkumar, 421623

ROPEG-INTERFERON THERAPY IN POLYCYTHEMIA VERA: CLINICAL CONSIDERATION REGARDING EFFICACY AND SAFETY FROM A REAL-WORLD UNICENTRIC COHORT

EHA Library, Andrea Duminuco, 421624

RELATIONSHIP OF LYMPHOCYTE SUBSETS AND PROGNOSIS IN JUVENILE MYELOMONOCYTIC LEUKEMIA

EHA Library, Yunlong Chen, 421625

MOLECULAR AND HISTOPATHOLOGICAL CHARACTERISTICS OF MYELOPROLIFERATIVE NEOPLASMS ASSOCIATED WITH USUAL SITE THROMBOSIS.

EHA Library, Erika Morsia, 421626

DISEASE MANIFESTATIONS OF IDIOPATHIC HYPEREOSINOPHILIC SYNDROME: A SYSTEMATIC LITERATURE REVIEW

EHA Library, Priya Jain, 421628

IMPACT OF PROPHYLACTIC TREATMENT ON THIAMINE AND GASTROINTESTINAL ADVERSE EVENTS IN PATIENTS WITH MYELOFIBROSIS TREATED WITH FEDRATINIB IN THE FREEDOM2 TRIAL

EHA Library, Jean-Jacques Kiladjian, 421629

REAL-WORLD EXPERIENCE OF PEGYLATED INTERFERON ALFA-2B FOR MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Qing Leng, 421630

ESTRADIOL AND HYPERCOAGULABILITY IN CALR-MUTANT PRIMARY MYELOFIBROSIS

EHA Library, Rossella Cacciola, 421631

JAKCALC: A MACHINE-LEARNING APPROACH TO RATIONALIZED JAK2 TESTING IN PATIENTS WITH ELEVATED HEMOGLOBIN LEVELS

EHA Library, Fatos KOSEOGLU, 421632

MONOCYTES SUBSETS DISTRIBUTION IN HISTIOCYTOSIS: KEY MARKER FOR DISEASE CHARACTERIZATION AND STAGING.

EHA Library, Sylvain Audia, 421633

ABSENCE OF THE ATM P.L2307F GERMLINE VARIANT IN 121 ITALIAN PEDIGREES WITH FAMILIAL MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Oscar Borsani, 421634

THE PATTERNS AND ORGAN TREATMENT RESPONSE OF ERDHEIM-CHESTER DISEASE WITH CARDIAC INVOLVEMENT

EHA Library, Xin-xin Cao, 421635

PHASE 3 RANDOMIZED DOUBLE-BLIND STUDY EVALUATING SAFETY AND EFFICACY OF SELINEXOR, AN XPO1 INHIBITOR, PLUS RUXOLITINIB IN JAKI-NAÏVE MYELOFIBROSIS

EHA Library, Claire Harrison, 421636